Robert E. Bancroft, President and CEO and Director of AEON Biopharma, Inc., filed a Form 4 on November 20, 2026, disclosing an open-market purchase of Class A Common Stock on November 19, 2026.

Key Highlights

  • Shares acquired: 152,333 shares of Class A Common Stock purchased on November 19, 2026.
  • Weighted average price: $0.1286 per share, with individual transaction prices ranging from $0.1213 to $0.1345 per share.
  • Resulting ownership: Bancroft directly holds 3,329,436 shares of Class A Common Stock following the transaction.
  • Transaction code: P (open-market purchase), reported directly owned.
  • Reporting person roles: Bancroft is identified in the filing as both a Director and the President and CEO of AEON Biopharma, Inc.

Robert E. Bancroft's November 2026 Purchase of AEON Biopharma Class A Shares

According to the Form 4 filed with the SEC on November 20, 2026, Robert E. Bancroft, President and CEO and a Director of AEON Biopharma, Inc. (NASDAQ:AEON), acquired 152,333 shares of Class A Common Stock on November 19, 2026, through an open-market purchase coded "P" in the filing. The filing reports a weighted average purchase price of $0.1286 per share.

The filing notes in a footnote that the reported price is a weighted average and that the shares were purchased across multiple transactions at prices ranging from $0.1213 to $0.1345 per share, inclusive. The filing states that Bancroft "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."

Following the reported transaction, Bancroft's direct beneficial ownership in AEON Biopharma stands at 3,329,436 shares of Class A Common Stock, according to the filing. No derivative securities transactions were reported in Table II of the form. The form was signed by Alexander Wilson as Attorney-in-Fact for Robert E. Bancroft and dated November 20, 2026.

What Was Disclosed

The filing discloses an open-market purchase by AEON Biopharma's President and CEO of 152,333 Class A Common shares on November 19, 2026, at a weighted average price of $0.1286, bringing his direct holdings to 3,329,436 shares.